University of Miami
University of Miami
Miami, Florida, United States327 results · Page 1 of 14
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-10-09 | NCT07441694 | |
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) | Cytopenia, Evans syndrome, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-10-09 | NCT07421167 | |
| A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) | Leg Ulcer, Skin Ulcer, Skin and Connective Tissue Diseases, Varicose Ulcer, cardiovascular disorder, skin disorder, varicose disease, vascular disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06568627 | |
| A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT03701334 | |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, biliary tract cancer, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, carcinoma, cervix disorder, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, lung cancer, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder, transitional cell carcinoma, urothelial carcinoma, uterine disorder | Recruiting | Phase 1 | 2026-10-08 | NCT06293898 | |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT07007312 | |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Chemically-Induced Disorders, Digestive System Diseases, alcohol-induced disorders, alcohol-related disorders, alcoholic hepatitis, alcoholic liver disease, hepatitis, liver disorder, substance-related disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07428538 | |
| Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib | Skin and Connective Tissue Diseases, alopecia, alopecia areata, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Active, not recruiting | Not stated | 2026-10-06 | NCT06531109 | |
| DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers | Neuroendocrine Neoplasms | Active, not recruiting | Phase 1 | 2026-10-06 | NCT06132113 | |
| Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations | IDH1-Mutated Malignancies; Mutations; Targeted Therapy | Recruiting | Phase 2 | 2026-10-05 | NCT07032727 | |
| Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib | Mutant IDH1 Inhibitor Olutasidenib | Recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT06445959 | |
| Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, acute kidney injury, kidney disorder, kidney failure, urinary system disorder | Recruiting | Phase 3 | 2026-10-05 | NCT05399537 | |
| The Application of Lifestyle Enhancing Validated Integrative Therapies for Everyday Pain in Cirrhosis | Chronic Pain, Fibrosis, Neurobehavioral Manifestations, Neurologic Manifestations, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, agnosia, nervous system disorder, perceptual disorders | Not yet recruiting | Not applicable | 2026-10-02 | NCT07792850 | |
| Brain-Controlled Spinal Stimulation Walking Therapy After Incomplete Spinal Cord Injury (SCI) | central nervous system disorder, injury, nervous system disorder, nervous system injury, spinal cord disorder, spinal cord injury | Active, not recruiting | Not applicable | 2026-10-02 | NCT06406855 | |
| A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT04176198 | |
| The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | bronchial disorder, bronchiectasis, respiratory system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06872892 | |
| Florida Community-Engaged Research Alliance (FL-CEAL) | Health, Subjective | Recruiting | Not applicable | 2026-10-01 | NCT06829485 | |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 2 | 2026-10-01 | NCT06798896 | |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-01 | NCT06424288 | |
| Parasitic Ulcer Treatment Trial | Acanthamoeba keratitis, Infections, amebiasis, corneal disorder, corneal ulcer, eye disorder, eye infectious disorder, keratitis, parasitic eye infection, parasitic infectious disease, protozoa infectious disease | Recruiting | Phase 3 | 2026-10-01 | NCT06213649 | |
| A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-30 | NCT07843940 | |
| A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | Drug Resistant Epilepsy, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06132893 | |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemorrhage, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Hemorrhagic, Urogenital Diseases, diabetes insipidus, endocrine system disorder, injury, kidney disorder, pituitary gland disorder, urinary system disorder | Recruiting | Phase 2 | 2026-09-29 | NCT05958342 | |
| Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI) | Peripheral Nerve Injuries, injury, nervous system disorder, nervous system injury, neuromuscular disease, peripheral nervous system disorder | Recruiting | Phase 1 | 2026-09-29 | NCT05541250 | |
| Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass | Blood Protein Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, hematologic disorder, hereditary antithrombin deficiency, hereditary disease, inherited blood coagulation disorder, thrombophilia | Recruiting | Phase 3 | 2026-09-28 | NCT06096116 |